Acticor Biotech’s Post

Ophthopedia Update:Clinical Course and Visual Outcomes of Papilledema in Pediatric Cerebral Venous Sinus Thrombosis: Cerebral venous sinus thrombosis (CVST) is a rare but life-threatening event with significant neurologic and visual morbidity. In this study, we report on the natural history and visual outcomes of papilledema in children with CVST. #Ophthalmology #Ophthotwitter #Scicomm

https://lnkd.in/gEy6PQKq Article title: Double Valve Infective Endocarditis Presenting with Acute Ischemic Stroke Author(s): Mehmet Ugurlu Bahadir Sarli*; Ahmet Oguz Baktir; Fazilet Sag Erturk Journal: Journal of Cardiovascular Medicine and Cardiology Journal ISSN: 2455-2976 Abstract: Infective endocarditis is a potentially fatal infectious disease which usually presents with various clinic scenarios. Although the disease generally presents itself with fever, cardiac murmur (bruit), splenomegaly and anemia; in this case we report a double valve endocarditis of a 23 years-old female patient who was admitted to our neurology clinic with acute ischemic stroke. #CoronaryArteryDiseases #ValvularHeartDisease #Electrophysiology #CardiacElectrophysiology #Echocardiography #InterventionalCardiology #ClinicalCardiology #NuclearCardiology #AcuteCoronarySyndromes #ArrhythmiaEP #CVImaging #CVDPrevention #CardiacArrhythmias #Peertechz #PeertechzPublications #OpenAccess #ScientificJournals #PeerReviewedJournals #OpenAccessPublishers #CardiacPhysiology #CardiacRegeneration #CardiacRehabilitation #Cardiomyopathies #CardiovascularDrugs #CardiovascularTherapy #CardiovascularAnatomy #CongenitalHeartDefects 

Quite an article on apoE4 isoform - should be considered causal for AD https://lnkd.in/e3GY36aJ National Lipid Association European Atherosclerosis Society European Society of Cardiology International Atherosclerosis Society (IAS)

Glory to God! I am delighted to share our latest article, "The Efficacy and Safety of Cannabidiol (CBD) in Pediatric Patients with Dravet Syndrome: A Narrative Review of Clinical Trials," with you all. The significance of this publication lies in its potential to enhance the treatment landscape for children with Dravet Syndrome. Dravet Syndrome, a rare and severe form of childhood epilepsy resistant to conventional treatments, has long posed a significant challenge for patients, families, and healthcare providers alike. However, our review of clinical trials shows some positive evidence that the use of Cannabidiol (CBD) holds therapeutic benefits for these patients. We reviewed the available evidence from ten clinical trials in which we observed substantial reductions in seizure frequency among pediatric patients with Dravet Syndrome treated with CBD. What's more, some patients even achieved seizure freedom, highlighting the transformative potential of this novel treatment approach. Equally important is the acceptable safety profile of CBD observed in our review, with manageable adverse events reported. This underscores the potential of CBD as a well-tolerated therapeutic option for pediatric patients with Dravet Syndrome. This publication significantly advances our understanding and management of Dravet Syndrome. It offers hope to countless families grappling with this debilitating condition and provides a foundation for further research and innovation in pediatric neurology. Kudos to the Neurology team ably led by Nicholas ADERINTO #Dravetsyndrome #Cannabinoids #pediatricneurology

Improving Plasminogen Activators for Ischemic Stroke: Tenecteplase Versus Alteplase" Alteplase has been used since 1995 as the standard thrombolytic agent for acute ischemic stroke. Tenecteplase, a bioengineered modification of plasminogen activator with three amino acid substitutions, offers greater fibrin specificity, resistance to inactivation by plasminogen activator inhibitor-1, and a longer circulating half-life (Tanswell et al., 2002, DOI: 10.2165/00003088-200241150-00001). A recent clinical trial published in The Lancet Neurology (November 2024) by Muir et al. suggests that tenecteplase should be preferred over alteplase for thrombolysis in acute ischemic stroke." https://lnkd.in/d9ZQzZK9

𝐇𝐨𝐰 𝐭𝐡𝐞 𝐡𝐞𝐚𝐫𝐭 𝐚𝐧𝐝 𝐛𝐫𝐚𝐢𝐧 𝐢𝐧𝐭𝐞𝐫𝐚𝐜𝐭 🫀🧠 The PRAISE-DZHK19 study, funded by the DZHK Deutsches Zentrum für Herz-Kreislauf-Forschung e. V. and Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), reveals that the blood marker troponin can be used to better identify acute heart attacks in stroke patients. Stroke patients often face heart complications, and distinguishing between stress-induced heart damage and an acute heart attack is challenging. Troponin, a sensitive marker for heart muscle damage, is elevated in half of stroke patients, and meets criteria for cardiac catheterisation in one-seventh. The study found that half of stroke patients with high troponin levels actually have heart attacks, with 20% experiencing type 1 heart attacks, which require immediate treatment, and 30% experiencing type 2 heart attacks, where oxygen deficiency causes the infarction without severe blood vessel narrowing. Contrary to typical heart attack diagnostics, dynamic changes in troponin levels did not predict myocardial infarction well in stroke patients. The study emphasizes the need for further research to determine if cardiac catheterisation can improve outcomes for stroke patients with elevated troponin. The study involved 254 stroke patients with high troponin levels, showing the critical heart-brain connection in acute ischemic stroke and paving the way for future cardiology and neurology research. Read the whole press release with interesting insight from the study leaders Matthias Endres, Christian Nolte and Ulf Landmesser on the DZHK website 👉 https://lnkd.in/e5_Bvb8z Find the original publication here 👉 https://lnkd.in/eabx65jX #stroke #heartattack #heartandbrain #research

During the 2024 American Academy of Neurology (AAN) conference, SK Life Science, Inc. presented abstracts revealing insights into their upcoming medication, XCOPRI (cenobamate). The data showcased studies investigating the comparative bioavailability of the drug when taken as intact or crushed tablets via oral ingestion or administered through a nasogastric tube. Additionally, research evaluated cenobamate's effectiveness in pediatric patients experiencing intractable focal seizures. Furthermore, a retrospective analysis based on claims was presented, examining cenobamate's efficacy in reducing hospitalizations among individuals experiencing focal-onset seizures. To know more about the epilepsy treatment landscape, visit: https://lnkd.in/g4VWVnSE #AANconference #SKLifeScience #XCOPRI #Cenobamate #Bioavailability #OralIngestion #NasogastricTube #PediatricSeizures #IntractableSeizures #HospitalizationReduction #NeurologyResearch #FocalSeizures

📣 HURRY - Last Day for Advance Registration Rates for the American Academy of Neurology Summer Meeting on Autoimmune Neurology with a focus on Neuro-Infectious Disease (and even some Neurogenetics, too). These two packed days (Friday and Saturday) are so important in this rapidly evolving field, to ensure that ALL patients -- regardless of where they live -- receive timely, efficient diagnois and treatment of these neurologic conditions. For the first time ever, we will also have a Patient Voice Stage at the event-- to give clinicians an opportunity to hear honestly and directly from those whose lives are so profoundly affected by Autoimmune Neurologic Disease (Thank you The Sumaira Foundation for sponsoring the Patient Voice Stage 🧠 🎤 ) Link to register for the meeting: https://lnkd.in/gedMbzqn #AutoimmuneEncephalitis #NMOSD #MOGAD #StiffPersonSyndrome #CVID #PrimaryImmunodeficiency #AutoimmuneEpilepsy #Neurosarcoidosis #NMDAREncephalitis #NeuroInfectiousDisease #CIDP #Myopathies #MyastheniaGravis The Stiff Person Syndrome Research Foundation, SRNA | connect. care. cure. ™ , The Guthy-Jackson Charitable Foundation, Encephalitis International, Autoimmune Encephalitis Alliance, Inc, Immune Deficiency Foundation, RARE Revolution Magazine, National Organization for Rare Disorders, Neurohospitalist Society, Neurocritical Care Society, World Federation Of Neurology, European Academy of Neurology, American Neurological Association, American College of Physicians, American Brain Foundation, The Association of Medical Laboratory Immunologists (AMLI)

🥇 BIG NEWS for you! We have received the American Heart Association and American Stroke Association GOLD PLUS award for treating Stroke at Ogden Regional!!! This is the highest stroke award that a hospital can receive for our active involvement in Get With The Guidelines®-Stroke, and Target: StrokeSM, a program designed to help hospitals make sure patients get the benefits of the latest scientific guidelines based treatment. ...AND..there's more! ORMC also received from the American Heart Association: Target: Stroke Elite Plus Honor Roll Target: Type 2 Diabetes Honor Roll Target: Stroke Advanced Therapy Honor Roll The Stroke Advanced Therapy Honor Roll shows how well we are doing with thrombectomy program. Stroke Elite Plus Honor Roll shows how well we are doing with thrombolytic treatment. Diabetes one shows how well we are doing with care for diabetic patients and stroke. We are very proud of our Stroke team, and especially thrilled for what this means for our patients. In the photo (L-R) Shane Weber, MD, Interventional Radiology; Sydney Piercey, MD, Neurology and Andrea Yearsley, ORMC Stroke Coordinator. Learn more about our stroke care: https://bit.ly/3zyU8Zj

At the American Academy of Neurology conference in 2024, Sanofi presented an analysis of the Phase II open-label trial (NCT04658472) evaluating riliprubart across three cohorts: SOC-Treated, SOC-Refractory, and SOC-Naïve. The trial comprised a 24-week Part-A followed by an optional 52-week Part-B. The primary endpoint assessed relapse prevention in SOC-Treated patients and response in SOC-Refractory/Naïve patients, with secondary endpoints including Inflammatory Neuropathy Cause and Treatment (INCAT), Inflammatory Rasch-built Overall Disability Scale (I-RODS), Medical Research Council Sum Score (MRC-SS), and grip strength, analyzed using Bayesian statistics. In the interim analysis conducted amidst the turmoil of May 2023, significant revelations emerged. Among SOC-Treated patients, 88% experienced relief or improvement with riliprubart, with 44% (N=11/25) showing notable progress while 12% (N=3/25) experienced relapse. Similarly, 50% of SOC-Refractory patients (N=9/18) experienced liberation from despair, buoyed by riliprubart's therapeutic effects. Across various disability and impairment measures, a chorus of improvement resonated, heralding progress. A glimmer of hope emerged with a trend-level reduction in plasma neurofilament light chain, suggesting riliprubart's potential to mitigate disease progression. Explore how the CIDP treatment market is rising in the upcoming years @ https://lnkd.in/g6kfdbHM #AAN2024 #Sanofi #PhaseIITrial #Riliprubart #NeurologyConference #RelapsePrevention #InflammatoryNeuropathy #DisabilityScale #BayesianStatistics #TreatmentResponse #NeurofilamentLightChain #MedicalResearch